Debt-to-equity in % of ELITE PHARMACEUTICALS INC /NV/ from Q4 2011 to Q3 2025

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
ELITE PHARMACEUTICALS INC /NV/ quarterly Debt-to-equity history and change rate from Q4 2011 to Q3 2025.
  • ELITE PHARMACEUTICALS INC /NV/ Debt-to-equity for the quarter ending 30 Sep 2025 was 109 %, a 82.3% increase year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Change (%)

ELITE PHARMACEUTICALS INC /NV/ Quarterly Debt-to-equity (%)

Period Value YoY Chg Change % Date
Q3 2025 109 +49.1 +82.3% 30 Sep 2025
Q2 2025 109 +56.3 +106% 30 Jun 2025
Q1 2025 85.8 +32 +59.6% 31 Mar 2025
Q4 2024 75.6 +21 +38.5% 31 Dec 2024
Q3 2024 59.6 +2.67 +4.69% 30 Sep 2024
Q2 2024 52.9 -10.7 -16.9% 30 Jun 2024
Q1 2024 53.8 -17.9 -25% 31 Mar 2024
Q4 2023 54.6 -17.7 -24.5% 31 Dec 2023
Q3 2023 56.9 -7.41 -11.5% 30 Sep 2023
Q2 2023 63.6 +8.5 +15.4% 30 Jun 2023
Q1 2023 71.7 +25.3 +54.4% 31 Mar 2023
Q4 2022 72.3 +20.4 +39.2% 31 Dec 2022
Q3 2022 64.3 +3.93 +6.51% 30 Sep 2022
Q2 2022 55.1 -15.1 -21.5% 30 Jun 2022
Q1 2022 46.4 -39.9 -46.2% 31 Mar 2022
Q4 2021 52 -51.1 -49.6% 31 Dec 2021
Q3 2021 60.4 -66 -52.2% 30 Sep 2021
Q2 2021 70.1 -134 -65.6% 30 Jun 2021
Q1 2021 86.3 -280 -76.4% 31 Mar 2021
Q4 2020 103 -3.1K -96.8% 31 Dec 2020
Q3 2020 126 +785 30 Sep 2020
Q2 2020 204 +1.94K 30 Jun 2020
Q1 2020 366 -1.98K -84.4% 31 Mar 2020
Q4 2019 3.2K +2.68K +508% 31 Dec 2019
Q3 2019 -659 -968 -313% 30 Sep 2019
Q2 2019 -1.73K -1.97K -816% 30 Jun 2019
Q1 2019 2.34K +2.09K +813% 31 Mar 2019
Q4 2018 527 +409 +348% 31 Dec 2018
Q3 2018 310 +234 +307% 30 Sep 2018
Q2 2018 242 +181 +298% 30 Jun 2018
Q1 2018 257 +144 +128% 31 Mar 2018
Q4 2017 118 +509 31 Dec 2017
Q3 2017 76.1 +154 30 Sep 2017
Q2 2017 60.8 +120 30 Jun 2017
Q1 2017 113 +179 31 Mar 2017
Q4 2016 -391 -322 -465% 31 Dec 2016
Q3 2016 -78 +34.5 +30.6% 30 Sep 2016
Q2 2016 -58.9 +70.8 +54.6% 30 Jun 2016
Q1 2016 -66.4 +65.1 +49.5% 31 Mar 2016
Q4 2015 -69.3 +69.7 +50.1% 31 Dec 2015
Q3 2015 -112 +27.6 +19.7% 30 Sep 2015
Q2 2015 -130 +17.9 +12.1% 30 Jun 2015
Q1 2015 -131 +40.1 +23.4% 31 Mar 2015
Q4 2014 -139 +182 +56.8% 31 Dec 2014
Q3 2014 -140 +108 +43.6% 30 Sep 2014
Q2 2014 -148 +37.6 +20.3% 30 Jun 2014
Q1 2014 -172 -8.47 -5.19% 31 Mar 2014
Q4 2013 -321 -165 -105% 31 Dec 2013
Q3 2013 -248 -93.2 -60.1% 30 Sep 2013
Q2 2013 -185 -30.6 -19.8% 30 Jun 2013
Q1 2013 -163 -16.3 -11.1% 31 Mar 2013
Q4 2012 -156 -9.53 -6.49% 31 Dec 2012
Q3 2012 -155 30 Sep 2012
Q2 2012 -155 30 Jun 2012
Q1 2012 -147 31 Mar 2012
Q4 2011 -147 31 Dec 2011
* An asterisk sign (*) next to the value indicates that the value is likely invalid.